Nystatin Topical Powder 100000 U/g Powder, 15 g — NDC 42806-178-15 (Billing 42806-0178-15)
This is a package of 15 g of Nystatin Topical Powder 100000 U/g Powder from Epic Pharma, LLC, marketed since May 2018 and currently FDA-listed; retail pharmacies pay about $0.3072 per g (NADAC). It is the main listing for this product, which comes in 3 package sizes.
NDC database record
One package, one record: these facts belong to NDC 42806-178-15 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 42806 labeler · 178 product · 15 package
- Package marketed since
- May 2, 2018
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 15 g per package
- Barcode (UPC-A, from the NDC)
- 3 4280617815 7
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007284
- GCN: 30160
- GPI-14 (Medi-Span): 90150080002920
- HICL (First Databank): 004129
- AHFS class code: 08:14.28.00
- RxCUI (RxNorm): 646456
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Polyene Antifungal class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 8, 2026
Clinical
Topical nystatin is used to treat fungal infections of the skin. Nystatin is in a class of antifungal medications called polyenes. It works by stopping the growth of fungi that cause infection.
Read the full MedlinePlus article ↗- It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
- Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
- How do I use the liquid for a mouth infection?
- Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.307 | $4.61 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.3744 | $5.62 / 15 g |
Where does this data come from?
- CMS NADAC weekly file · file of Jun 22, 2022
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 9, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 42806-0178-15 You're viewing this Main listing | 15 g in 1 BOTTLE | $0.3072 / g | $4.61 | 2018-05-02 | — | Active |
| 42806-0178-30 42806-178-30 | 30 g in 1 BOTTLE | $0.2683 / g | $8.05 | 2018-05-02 | — | Active |
| 42806-0178-60 42806-178-60 | 60 g in 1 BOTTLE | $0.2254 / g | $13.53 | 2018-05-02 | — | Active |
You're viewing the smallest of 3 pack sizes for this product.
Per g, this pack runs about 36% above the cheapest pack (60 g, $0.2254 vs $0.3072 NADAC).
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 42806-0178-30?
What NDC number is used to bill for this package of Nystatin Topical Powder 100000 U/g Powder?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Nystop 100000 [USP'U]/g 00574-2008-02 | Padagis | 60 g | $0.257 | AT | Availability likely | save 16% |
| Nystatin Topical Powder 100000 U/gthis 42806-0178-15 | Epic | 15 g | $0.307 | AT | FDA listed | — |
| Nystatin 100000 [USP'U]/g 75907-0060-30 | Dr. | 30 g | $0.313 | AT | Availability likely | +2% |
| Nyamyc 100000 [USP'U]/g 00832-0465-15 | Upsher-Smith | 1 bottle | $0.421 | AT | Availability likely | +37% |
| Klayesta 100000 U/g 42806-0186-15 | Epic | 15 g | $0.421 | AT | Availability likely | +37% |
| Nystatin 100000 [USP'U]/g 68382-0370-01 | Zydus | 15 g | $0.421 | AT | Availability likely | +37% |
| Nystatin 100000 [USP'U]/g 69315-0306-15 | Leading | 15 g | $0.421 | AT | Availability likely | +37% |
| Nystatin 100000 [USP'U]/g 72603-0491-01 | Northstar | 15 g | $0.421 | AT | Availability likely | +37% |
| Nystatin Topical Powder 100000 U/g 42806-0185-15 | Epic | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8696-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8697-01 | Bryant | 30 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8698-01 | Bryant | 60 g | — | AT | FDA listed | — |
| Nystatin 100000 [USP'U]/g 70771-1585-01 | Zydus | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 71335-2845-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 71335-2869-01 | Bryant | 30 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 72162-1124-02 | Bryant | 15 g | — | AT | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 9, 2026
- CMS NADAC weekly file · file of Jun 22, 2022
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 9, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Nystatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 7SEV7J4R1U
A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Epic Pharma, LLC labeler code 42806
- AZITHROMYCIN 200 mg/5mL Powder, For Suspension NDC 42806-149-32
- AZITHROMYCIN 200 mg/5mL Powder, For Suspension NDC 42806-150-33
- AZITHROMYCIN 200 mg/5mL Powder, For Suspension NDC 42806-151-34
- Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated NDC 42806-159-01
- Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated NDC 42806-160-01
- Hydroxyzine Hydrochloride 50 mg Tablet, Film Coated NDC 42806-161-01
- Nystatin Topical Powder 100000 U/g Powder NDC 42806-185-15
- KLAYESTA Nystatin Topical Powder 100000 U/g Powder NDC 42806-186-15
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-265-98
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-266-95
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-267-93
- Cholestyramine Light 4 g/5.7g Powder, For Suspension NDC 42806-269-98
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
⛔ Contraindications ▾
CONTRAINDICATIONS Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS, General .)
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION ).
🧓 Geriatric Use ▾
Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.
On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C, tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.
This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Nystatin topical powder, USP is supplied as 100,000 units nystatin per gram in plastic squeeze bottles. 15 g (NDC 42806-178-15) 30 g (NDC 42806-178-30) 60 g (NDC 42806-178-60)
📦 Storage and Handling ▾
STORAGE Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed. Distributed by: Epic Pharma, LLC Laurelton, NY 11413 Rev. 05-2018-00 MF178REV05/2018 OE2722
📋 Description ▾
DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. The molecular formula for Nystatin is C 47 H 75 NO 17 . The molecular weight of Nystatin is 926.09. Structural formula: Nystatin topical powder is for dermatologic use. Nystatin topical powder contains 100,000 USP nystatin units per gram dispersed in talc. nystatin-topical-powder-structural-formula
💬 Information for Patients ▾
Information for Patients Patients using this medication should receive the following information and instructions: 1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3.
If symptoms of irritation develop, the patient should be advised to notify the physician promptly.
⚠️ Precautions ▾
PRECAUTIONS General Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.
Information for Patients Patients using this medication should receive the following information and instructions: 1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3.
If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin.
No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.
Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.
Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION ). Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects.
Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.
🧬 Pharmacokinetics ▾
Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.
🧬 Pharmacodynamics ▾
Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin.
Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C, tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.
Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 15 grams Nystatin Topical Powder, USP 100,000 units per gram 15 grams FOR TOPICAL USE ONLY Not for Ophthalmic Use Rx Only front-panel.jpg